JGJingli Guo

Jingli Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingli Guo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Wei Liu

    Eye Institute and Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, People’s Republic of China

    2 shared publications
  • Gezhi Xu

    Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Gezhi Xu

    Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai, China

    1 shared publication
  • Haixiang Wu

    Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China

    1 shared publication
  • Jiade Lu

    Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China

    1 shared publication
  • Jiayao Sun

    Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study

    by Jingli Guo, Xianxin Qiu, Wenyi Tang, Gezhi Xu, Michael. F. Moyers, Wei Ren, Ying Xing, Jin Gao, Jiayao Sun, Jiade Lu, et al.

    Introduction To investigate the efficacy and safety of proton-beam irradiation (PBI) combined with intravitreal conbercept (IVC) injection for refractory or recurrent polypoidal choroidal vasculopathy (PCV). Methods A prospective interventional clinical trial included 12 patients with refractory PCV (defined as persistent exudation or fluid after six consecutive injections at monthly intervals and/or photodynamic therapy) or recurrent PCV (defined as new exudative signs after six monthly injections and/or photodynamic therapy) treated between January 2019 and September 2020. Every patient underwent single PBI (14 GyE) with concomitant IVC (0.5 mg) within 1 week and further doses of IVC were administered pro re nata. Results By the 12-month follow-up, the subretinal fluid was completely absorbed in 9 eyes (81.8%). The angiographic regression and closure rates of the polyps were 60% (12/20) and 90% (18/20), respectively. The mean number of IVC injections was 3.1 ± 1.37. The mean BCVA improved by 20 letters (P = 0.006). The mean central macular thickness (CMT) decreased from 476.50 ± 123.63 μm to 317.70 ± 89.34 μm (P = 0.004). The areas of branching vascular networks and polyps decreased by 37.2% and 72.3%, respectively. Radiation retinopathy was observed in five eyes, but no systemic adverse events were observed. Conclusion PBI combined with IVC appears to promote polyp regression and closure, reduce CMT, and improve BCVA, with a favorable safety profile, after 12 months. Therefore, PBI may be a useful adjuvant therapy for patients with refractory or recurrent PCV. Trial Registration Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: Prospective Phase II Clinical Study (ChiCTR2000038987).


  • Open Access

    Predictive multi-imaging biomarkers relevant for visual acuity in idiopathic macular telangiectasis type 1

    by Jingli Guo, WenYi Tang, Xiaofeng Ye, Haixiang Wu, Gezhi Xu, Wei Liu, Yongjin Zhang

    To evaluate the structural changes associated with visual acuity (VA) in patients with idiopathic macular telangiectasia (MT) type 1 using multimodal imaging modalities. A retrospective study of 14 patients with MT type 1 and of 10 eyes from 10 healthy individuals as age-matched controls was conducted. The medical records of patients who had undergone colour fundus photography, spectral domain optical coherence tomography (OCT), fluorescein angiography and OCT angiography were reviewed. Central macular thickness (CMT), the areas of macular oedema and ellipsoid zone (EZ) disruption, EZ length, disorganization of the retinal inner layers (DRIL) and external limiting membrane (ELM) disruption, as measured by spectral domain OCT; and vascular density and the foveal avascular zones (FAZ) of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), as measured by OCT angiography, were assessed in MT type 1 eyes and correlated with VA. The mean baseline best-corrected VA of MT type 1 eyes was 0.45 ± 0.28. The mean CMT was 385.19 ± 75.21 μm in MT type 1 eyes and 252.43 ± 15.77 μm in contralateral eyes (Z = − 4.113, p < 0.001). The mean vessel density of the DCP was lower in MT type 1 eyes (47.25 ± 4.69%) than in contralateral eyes (53.93 ± 2.94%) and normal eyes (59.37 ± 2.50%) (Z = − 3.492, − 4.099; p < 0.001, < 0.001). The baseline logMAR VA was correlated with CMT (r = 0.682, p = 0.007), SCP density (r = − 0.652, p = 0.012), DCP density (r = − 0.700, p = 0.005), total area of EZ disruption (r = 0.649, p = 0.012); and total lengths of EZ (r = 0.681, p = 0.007), ELM (r = 0.699, p = 0.005) and DRIL (r = 0.707, p = 0.005) disruption in the 1-mm-diameter foveal region in MT type 1 eyes. Decreased DCP density and the presence of DRIL may be predictive biomarkers of VA in MT type 1. CMT, SCP density, total area of EZ disruption, and lengths of EZ and ELM disruption within the 1-mm-diameter central region were strongly associated with VA.